Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRETON vs METROGEL-VAGINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Treatment of bacterial vaginosis (FDA-approved),Off-label: Trichomoniasis, anaerobic bacterial infections
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Not extensively metabolized; primarily excreted unchanged in urine.
Hepatic metabolism via oxidation and glucuronidation; major metabolite: hydroxy-metronidazole (active).
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% unchanged; fecal/biliary: 6-15%
75-85% bound to albumin and alpha-1-acid glycoprotein
<20% bound; primarily to serum albumin (minimal binding)
0.5-1.0 L/kg; indicates moderate tissue distribution
0.25-0.85 L/kg (widely distributed to tissues, including vaginal mucosa and cerebrospinal fluid)
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
Intravaginal: Systemic bioavailability approximately 50-60% relative to oral; vaginal absorption variable (mean ~56% of oral dose)
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
No specific Child-Pugh based adjustments available. Use with caution in severe hepatic impairment due to potential metronidazole accumulation.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Safety and efficacy not established in pediatric patients; data insufficient for weight-based dosing.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
No specific dose adjustment required. Use standard dosing with consideration of age-related decline in renal function and potential for concurrent medications.
None
No FDA boxed warning.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Carcinogenicity: Avoid unnecessary prolonged use; rodent studies showed tumorigenicity.,Peripheral neuropathy: May occur with high doses or prolonged therapy.,Candidiasis: May overgrow Candida; treat concurrent infections.,Neutropenia: Monitor CBC if retreatment needed.,Alcohol interaction: Disulfiram-like reaction (abdominal cramps, nausea, vomiting) if alcohol consumed within 48 hours.,Hepatic impairment: Use with caution; dose adjustment may be needed.
Hypersensitivity to any component of the formulation
Hypersensitivity to metronidazole or nitroimidazoles,Pregnancy: Contraindicated in first trimester (use only if clearly needed in second/third trimester),Use with alcohol or propylene glycol,Use with disulfiram (within 2 weeks)
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Avoid alcohol and any products containing alcohol (e.g., certain sauces, vinegars, desserts, mouthwashes) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations, but some studies suggest a possible association with cleft lip/palate; use only if clearly needed. In the second and third trimesters, no increased risk of fetal abnormalities has been reported. Avoid use in preterm labor or premature rupture of membranes due to potential systemic absorption.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
Metronidazole is excreted in breast milk; after vaginal administration, systemic absorption is minimal (approximately 2% of oral dose), resulting in low milk concentrations. The M/P ratio is approximately 0.8-1.0 for oral dosing; for vaginal gel, ratio is expected lower. The American Academy of Pediatrics considers single-dose therapy compatible with breastfeeding after timed dosing and discarding milk for 12-24 hours. For chronic use, monitor infant for gastrointestinal disturbances.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
No dose adjustment is required for METROGEL-VAGINAL during pregnancy. Systemic absorption is low (<2%), and pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose modification for vaginal administration. Use standard dosage: one applicatorful (5 g containing 37.5 mg metronidazole) intravaginally once or twice daily for 5 days.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
Metronidazole vaginal gel is first-line for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Use caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. May cause metallic taste. Do not use during menstruation; treatment is typically 5 days but can be extended to 7-10 days for recurrent BV.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
Use the applicator to insert the gel into the vagina as directed, usually once or twice daily for 5 days.,Do not drink alcohol or use alcohol-containing products (mouthwash, cough syrup) during treatment and for 2 days after stopping.,You may notice a metallic taste in your mouth, which is common and harmless.,Avoid sexual intercourse or use condoms during treatment to prevent irritation and reinfection.,Wash hands before and after use. Do not use tampons, douches, or other vaginal products during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRETON vs METROGEL-VAGINAL, answered by our medical review team.
METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. METROGEL-VAGINAL is a Antibiotic (Nitroimidazole) that works by Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRETON and METROGEL-VAGINAL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. The standard adult dose of METROGEL-VAGINAL is: One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRETON and METROGEL-VAGINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. METROGEL-VAGINAL is classified as Category C. Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.